脓毒症相关急性肾损伤患者肾脏替代治疗启动时机的研究进展
急性肾损伤是危重症患者最常见的并发症之一,脓毒症是ICU中急性肾损伤的主要原因,重症可导致不良预后。对于有紧急透析指征的脓毒症相关急性肾损伤患者,目前已明确可立即启动肾脏替代治疗以控制疾病进展。然而,对于病情未严重到需要紧急透析的患者,启动肾脏替代治疗的最佳时机仍存在争议。既往部分研究样本量小且异质性大,缺乏指导脓毒症相关急性肾损伤患者肾脏替代治疗的有效参考指标。本文复习近年来治疗危重症急性肾损伤患者的相关实验研究,综述肾脏替代治疗最佳启动时机的最新研究进展,以期为临床实践提供有效参考。
要点
- 有紧急透析指征的脓毒症相关急性肾损伤患者,已明确可立即启动肾脏替代治疗以控制疾病进展。
- 病情未严重到需要紧急透析的脓毒症相关急性肾损伤患者,启动肾脏替代治疗的最佳时机仍存在争议。
- 既往部分相关研究样本量小且异质性大,缺乏指导脓毒症相关急性肾损伤患者肾脏替代治疗的有效参考指标。
- 本文综述近年危重症急性肾损伤患者肾脏替代治疗最佳启动时机的最新研究进展,以期为临床实践提供参考。
适用人群与场景
- ICU中脓毒症相关急性肾损伤患者,分为有紧急透析指征者和病情未严重到需要紧急透析者两类。
研究设计与关键结果
- 综述指出:有紧急透析指征的脓毒症相关急性肾损伤患者,已明确可立即启动肾脏替代治疗以控制疾病进展;未达紧急透析指征者最佳启动时机仍存争议。
- 既往部分研究样本量小且异质性大,缺乏指导脓毒症相关急性肾损伤患者肾脏替代治疗的有效参考指标。
证据类型、等级与局限
- 证据类型:综述。
- 局限:原文未报告局限性。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「对床旁实践的改变」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Acute kidney injury (AKI) is one of the most common complications in critically ill patients, and sepsis is the main cause of AKI in the intensive care unit (ICU), which can lead to a poor prognosis in severe cases. For patients with sepsis-associated acute kidney injury (SA-AKI) for whom urgent dialysis is indicated, it is now clear that renal replacement therapy (RRT) can be initiated immediately to control disease progression. However, the optimal timing to initiate RRT in patients whose disease is not severe enough to warrant urgent dialysis remains controversial. Some previous studies were small and heterogeneous, and there was a lack of effective reference indicators for guiding RRT in SA-AKI patients. Therefore, this article reviews the relevant experimental studies on the treatment of critically ill patients with AKI in recent years, and reviews the latest research progress on the optimal timing of RRT initiation, in order to provide an effective reference for clinical practice.
参考来源
- Yan Y, Guo H, Tan R, et al. [Research progress on the timing of initiation of renal replacement therapy in patients with sepsis-associated acute kidney injury]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2025. PMID: 41146515. doi:10.3760/cma.j.cn121430-20241008-00817
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。